191 related articles for article (PubMed ID: 23708664)
1. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells.
Cappello P; Blaser H; Gorrini C; Lin DC; Elia AJ; Wakeham A; Haider S; Boutros PC; Mason JM; Miller NA; Youngson B; Done SJ; Mak TW
Oncogene; 2014 May; 33(18):2375-84. PubMed ID: 23708664
[TBL] [Abstract][Full Text] [Related]
2. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer.
Hayward DG; Clarke RB; Faragher AJ; Pillai MR; Hagan IM; Fry AM
Cancer Res; 2004 Oct; 64(20):7370-6. PubMed ID: 15492258
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in centrobin and Nek2 are associated with breast cancer susceptibility in a Chinese Han population.
Wang H; Xie YT; Han JY; Ruan Y; Song AP; Zheng LY; Zhang WZ; Sajdik C; Li Y; Tian XX; Fang WG
Breast Cancer Res Treat; 2012 Nov; 136(1):241-51. PubMed ID: 23001753
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer.
Zeng YR; Han ZD; Wang C; Cai C; Huang YQ; Luo HW; Liu ZZ; Zhuo YJ; Dai QS; Zhao HB; Liang YX; Zhong WD
BMC Urol; 2015 Aug; 15():90. PubMed ID: 26320076
[TBL] [Abstract][Full Text] [Related]
5. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells.
Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI
Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253
[TBL] [Abstract][Full Text] [Related]
6. Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
Marina M; Saavedra HI
Front Biosci (Landmark Ed); 2014 Jan; 19(2):352-65. PubMed ID: 24389189
[TBL] [Abstract][Full Text] [Related]
7. Nek2 as a novel molecular target for the treatment of breast carcinoma.
Tsunoda N; Kokuryo T; Oda K; Senga T; Yokoyama Y; Nagino M; Nimura Y; Hamaguchi M
Cancer Sci; 2009 Jan; 100(1):111-6. PubMed ID: 19038001
[TBL] [Abstract][Full Text] [Related]
8. E2F activators signal and maintain centrosome amplification in breast cancer cells.
Lee MY; Moreno CS; Saavedra HI
Mol Cell Biol; 2014 Jul; 34(14):2581-99. PubMed ID: 24797070
[TBL] [Abstract][Full Text] [Related]
9. Nek2 kinase in chromosome instability and cancer.
Hayward DG; Fry AM
Cancer Lett; 2006 Jun; 237(2):155-66. PubMed ID: 16084011
[TBL] [Abstract][Full Text] [Related]
10. Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model.
Harrison Pitner MK; Saavedra HI
PLoS One; 2013; 8(6):e65971. PubMed ID: 23776583
[TBL] [Abstract][Full Text] [Related]
11. Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells.
Lee J; Gollahon L
Cell Cycle; 2013 Dec; 12(23):3599-614. PubMed ID: 24091727
[TBL] [Abstract][Full Text] [Related]
12. The Nek2 protein kinase: a novel regulator of centrosome structure.
Fry AM
Oncogene; 2002 Sep; 21(40):6184-94. PubMed ID: 12214248
[TBL] [Abstract][Full Text] [Related]
13. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis.
Li JJ; Li SA
Pharmacol Ther; 2006 Sep; 111(3):974-84. PubMed ID: 16603252
[TBL] [Abstract][Full Text] [Related]
14. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2.
Zeng X; Shaikh FY; Harrison MK; Adon AM; Trimboli AJ; Carroll KA; Sharma N; Timmers C; Chodosh LA; Leone G; Saavedra HI
Oncogene; 2010 Sep; 29(36):5103-12. PubMed ID: 20581865
[TBL] [Abstract][Full Text] [Related]
15. Silencing of E2F3 suppresses tumor growth of Her2+ breast cancer cells by restricting mitosis.
Lee M; Oprea-Ilies G; Saavedra HI
Oncotarget; 2015 Nov; 6(35):37316-34. PubMed ID: 26512919
[TBL] [Abstract][Full Text] [Related]
16. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators.
Fry AM; Meraldi P; Nigg EA
EMBO J; 1998 Jan; 17(2):470-81. PubMed ID: 9430639
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A; Padellan M; Marchenko N
Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of centrosome separation after DNA damage: a role for Nek2.
Fletcher L; Cerniglia GJ; Nigg EA; Yend TJ; Muschel RJ
Radiat Res; 2004 Aug; 162(2):128-35. PubMed ID: 15387139
[TBL] [Abstract][Full Text] [Related]
19. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
Lee J; Gollahon L
Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795
[TBL] [Abstract][Full Text] [Related]
20. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin.
Suzuki K; Kokuryo T; Senga T; Yokoyama Y; Nagino M; Hamaguchi M
Cancer Sci; 2010 May; 101(5):1163-9. PubMed ID: 20345485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
